T Cell Non-Hodgkin Lymphoma

The GSD index emerges as a robust prognostic tool for NK/T-HLH patients with hepatic dysfunction, reflecting underlying IFN-γ-mediated immunopathology. Early intervention with anti-IFN-γ monoclonal antibody may improve clinical outcomes in this high-risk subgroup.

Pediatric PCLs show heterogeneous behavior and therapeutic responses. Early biopsy of atypical or treatment-refractory eruptions, comprehensive histopathology and immunophenotyping, targeted EBV testing when suggested, and appropriate use of skin-directed radiotherapy (EBRT/TSEBT) and transplantation in selected refractory disease are essential. Multidisciplinary management and equitable access to specialized therapies are critical to optimize outcomes.

P=N/A, N=100, Not yet recruiting, Sun Yat-sen University

Consolidative allogeneic hematopoietic stem cell transplant HSCT then lead to long-term remission. This case underscores the critical role of comprehensive genomic profiling for rare histologies and supports the potential utility of JAK/STAT pathway inhibitors in select patients with ALK-negative ALCL.

P1, N=98, Recruiting, Schrödinger, Inc. | N=52 --> 98 | Trial completion date: Mar 2026 --> Nov 2027 | Trial primary completion date: Mar 2026 --> Nov 2027

P1, N=217, Recruiting, Ono Pharmaceutical Co. Ltd | Trial completion date: Mar 2027 --> Aug 2028 | Trial primary completion date: Mar 2026 --> Aug 2027

The anti-ICOSL neutralizing antibodies induced apoptosis and suppressed CCR4 expression on tumor cells, inhibiting CCR4-CCL17-mediated migration. These results suggest that the ICOS-ICOSL axis plays an essential role in CTCL pathogenesis, and targeting the ICOS-ICOSL axis could be a viable strategy for treating CTCL.

More innovative strategies include the use of ICIs in the context of allogeneic haematopoietic stem cell transplantation and chimeric antigen receptor T-cell therapy. This review synthesizes current evidence for the use of ICI in different haematological malignancies, and highlights future directions toward biomarker-driven, rationally designed therapeutic combinations.

This study provides a foundation for designing a new FC approach with TRBC1. This comprehensive review of the evolution of our laboratory practices may serve as a guide for other institutions with similar clinical needs.

P1/2, N=49, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting

This study highlights the aggressive nature of AITL and identifies several readily accessible laboratory parameters as important prognostic factors. The protective effect of PD-1 positivity on survival outcomes warrants further investigation. While CHOP/CHOPE remains the standard treatment, the addition of novel targeted therapies shows promise for improving patient outcomes in this challenging lymphoma subtype.